Market Newsdesk

VANCOUVER, British Columbia, Jan. 07, 2021 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd. (TSX-V: SYH)(OTCQB: SYHBF) (Frankfurt:SC1P) (the “Company”) is pleased to announce the remaining results from its 2020 fall diamond drilling program at its 100% owned, 35,705 hectare Moore Uranium Project, located approximately 15 kilometres east of Denison Mine’s Wheeler River project and proximal to regional infrastructure for Cameco’s Key Lake/McArthur River operations in the Athabasca Basin, Saskatchewan. In addition to the previously announced hole ML20-09 which returned 0.72% U₃O₈ over 17.5 metres from 271.5 metres to 289.0 metres, drillhole ML20-12 returned another broad zone of sandstone and basement-hosted uranium mineralization from 268.1 metres to 286.0 metres downhole. This intercept returned 0.28% U₃O₈ over 17.9 metres and contained a basal high grade basement intercept of 1.09% U₃O₈ over 2.5 metres. Up to 2.3% Cu was intersected in clay-altered lithologies nearly 100 metres below the unconformity in this hole as well.

Moore Uranium Project Claims Map:

http://skyharbourltd.com/_resources/maps/MooreLakeRegionalTenure.jpg

Highlights:

• Hole ML20-12 was drilled within the central portion of the Maverick East Zone. This hole intersected predominantly basement-hosted mineralization and returned 0.28% U₃O₈ over 17.9 metres from 268.1 metres to 286.0 metres including 1.09% U₃O₈ over 2.5 metres from 281.5 metres to 284.0 metres.
• Copper values of up to 2.3% were obtained from graphitic, clay-rich fractures within a broader zone of uranium-enriched and clay-altered granitic pegmatite and granite nearly 100 metres below the unconformity and the main mineralized zone.
• The mineralized intercept in hole ML20-12 is a discrete zone of mineralization hosted primarily in sheared, clay-altered to -replaced graphitic pelitic assemblages within the basement. This intercept confirms continuity within the central portion of the eastern extension of the Maverick East Zone. The eastern 50 metres of the Maverick East Zone has only marginally been drill tested to date and is open along strike and at depth in the basement rocks.
• Previously announced hole ML20-09 intersected predominantly basement-hosted mineralization and returned 0.72% U₃O₈ over 17.5 metres from 271.5 metres to 289.0 metres including 1.00% U₃O₈ over 10.0 metres from 279.0 metres to 289.0 metres.
• Both holes ML20-09 and ML20-12 represent two of the longest continuous drill intercepts of uranium mineralization discovered to date at the project.
• Hole ML20-13 extended the eastern extent of the Maverick East Zone by a minimum of 30 metres. This hole intersected predominantly basement-hosted mineralization and returned 0.24% U₃O₈ over 11.3 metres from 273.7 metres to 285.0 metres including 0.44% U₃O₈ over 3.5 metres from 281.5 metres to 285.0 metres.
• A greater understanding of the northeast extension of the Maverick Structural Corridor was also obtained by the drilling of a hole in the transitional area between the Viper and Esker targets. This drilling confirmed the geological model for this area and returned highly anomalous boron values (up to 1320 ppm B) in the basement rocks, along with significantly anomalous vanadium and nickel in the graphitic pelitic gneisses.
• Substantial portions of the 4.5-kilometre-long Maverick corridor remain to be systematically drill tested leaving robust discovery potential along strike as well as at depth in the basement rocks.
• Planning is underway for a fully funded winter drill program to commence in the coming months; details are forthcoming.

Jordan Trimble, President and CEO of Skyharbour Resources, stated: “We are very pleased with the results from this most recent drill program at our flagship Moore Project as we continue to discover new high grade uranium mineralization at the Maverick Corridor in relatively wide intercepts of continuous mineralization. We will be commencing a winter drill program to follow up on these results and test more extensively the highly prospective potential feeder zones in the basement rock at the Maverick Corridor. Skyharbour is very well positioned to benefit from the accelerating uranium market recovery with strong discovery potential and upcoming news flow from its continued drilling at Moore. Additional news flow will be provided by the work of partner companies Valor Resources, Orano Canada and Azincourt Energy each earning-in at our North Falcon Point, Preston and East Preston Projects, respectively.”

Summary of Final Results from Fall 2020 Drill Program:

The recently completed winter diamond drilling program totalled 2,560 metres in seven drill holes. These holes tested the Maverick West area (holes ML20-07 and ML20-08), the eastern portion of the Maverick East Zone (holes ML20-09, 10, 12 and 13) and a transitional zone between the Viper and Esker target areas (hole ML20-11). All the results have now been fully compiled and interpreted with planning for the upcoming 2021 winter diamond drilling program currently underway.

Moore Uranium Project Regional Grid Targets Map:

http://skyharbourltd.com/_resources/maps/Moore-Lake-Property-Wide.jpg

Hole ML20-12 was drilled to test for continuity of the mineralization within the eastern half of the Maverick East Zone. This hole intersected predominantly basement-hosted mineralization and returned 0.28% U₃O₈ over 17.9 metres from 268.1 metres to 286.0 metres including 1.09% U₃O₈ over 2.5 metres from 281.5 metres to 284.0 metres. Mineralization in the basal sandstone was hosted by desilcified, faulted and clay-altered sandstone while mineralization in the basement was hosted by a zone of clay replacement and graphitic shearing with massive to fracture controlled and disseminated uranium mineralization. The basement mineralization is accompanied by abundant As, Ni, and V. In addition to the mineralized zone, there is a notable 2.0 metre interval of copper enrichment bracketing a 0.5 metre interval of weak uranium mineralization (0.08% U₃O₈) nearly 100 metres below the unconformity. Copper values of up to 2.3% Cu were obtained from graphitic, clay-rich fractures within a broader zone of clay-altered granitic pegmatite and granite. The deep level of alteration associated with weak mineralization and highly anomalous copper geochemistry indicates the potential for delineation of a new mineralized zone at depth.

Moore Uranium Project Maverick Corridor Drilling Map:

https://www.skyharbourltd.com/_resources/maps/Fall-2020-Drilling-Maverick-Corridor-4.pdf

Drill hole ML20-10 was drilled as a 30-metre stepout northeast of ML20-04 which had intersected the easternmost extent of the Maverick East Zone in the winter of 2020. ML20-10 was drilled too far into the footwall and intersected structurally disrupted and clay-altered to replaced sandstone and granite but contained no significant uranium mineralization. This hole did return a typical footwall geochemical signature, with intense boron enrichment (up to 2620 ppm B) in the sandstone as well as elevated uranium, nickel, and other pathfinders in the sandstone and basement rocks.

Moore Uranium Project Main and East Maverick Zones Drilling Map:

https://www.skyharbourltd.com/_resources/maps/Fall-2020-Maverick-East-detail.pdf 

Drill hole ML20-11 was drilled in the area between the Esker and Viper targets to test for mineralization and establish the lithological and structural linkage between the two areas. This hole intersected a sandstone column with elevated uranium values locally. A significant package of locally faulted and altered graphitic pelitic gneiss was intersected over a downhole length of 60 metres. Although no significant uranium mineralization was intersected, strongly anomalous pathfinder elements such as B (1320 ppm), V (408 ppm), Ni (264 ppm), and Cu (220 ppm) associated with graphitic faults were intersected. This hole added to the understanding of the geological model for the northeast extension of the Maverick Structural Corridor.

Moore Uranium Project Esker-Viper Area Drilling Map:

https://www.skyharbourltd.com/_resources/maps/Fall-2020-Drilling-Esker-Viper-area.pdf

Drill hole ML20-13 was collared down-dip of hole ML20-10 which was determined to be a footwall hole. ML20-13 intersected a discrete interval of uranium mineralization straddling the unconformity beginning at 273.7 metres down hole and grading 0.24% U₃O₈ over 11.3 metres and includes a basal intercept of 0.44% U₃O₈ over 3.5 metres. Mineralization in the sandstone is hosted by clay-enriched and -replaced desilicified sandstone, while the basement-hosted mineralization is within clay-altered to -replaced and sheared graphitic pelitic gneiss. The sandstone and basement are also both highly enriched in pathfinder elements including boron.

Upcoming Exploration and Winter 2021 Drill Program:

Skyharbour has initiated permitting for geophysical and diamond drilling programs to take place in the winter and summer seasons of 2021. Specific details on the programs are forthcoming but the drilling will follow-up on both unconformity and basement targets along the high grade Maverick corridor, as well as targets identified by the geophysical program and essentially untested prospective conductive corridors identified by Skyharbour’s technical team. Of particular interest are potential underlying basement feeder zones to the unconformity-hosted, drill-indicated high-grade uranium mineralization along the Maverick corridor. These targets have seen limited historical drill testing.

Qualified Person:

The technical information in this news release has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 and reviewed and approved by Richard Kusmirski, P.Geo., M.Sc., Skyharbour’s Head Technical Advisor and a Director, as well as a Qualified Person. 

About Skyharbour Resources Ltd.:

Skyharbour holds an extensive portfolio of uranium and thorium exploration projects in Canada’s Athabasca Basin and is well positioned to benefit from improving uranium market fundamentals with six drill-ready projects. Skyharbour has acquired from Denison Mines, a large strategic shareholder of the Company, a 100% interest in the Moore Uranium Project which is located 15 kilometres east of Denison’s Wheeler River project and 39 kilometres south of Cameco’s McArthur River uranium mine. Moore is an advanced stage uranium exploration property with high grade uranium mineralization at the Maverick Zone that returned drill results of up to 6.0% U₃O₈ over 5.9 metres including 20.8% U₃O₈ over 1.5 metres at a vertical depth of 265 metres.

Skyharbour has option agreements with Orano Canada Inc. and Azincourt Energy whereby Orano and Azincourt can earn in up to 70% of the Preston and East Preston Projects, respectively, through a combined $9,800,000 in total exploration expenditures, as well as $1,700,000 in total cash payments and Azincourt shares. Preston and Preston East are large, geologically prospective properties proximal to Fission Uranium’s Triple R deposit as well as NexGen Energy’s Arrow deposit.

The Company owns a 100% interest in the South Falcon Uranium Project on the eastern perimeter of the Basin which contains a NI 43-101 inferred resource totaling 7.0 million pounds of U₃O₈ at 0.03% and 5.3 million pounds of ThO₂ at 0.023%. Skyharbour has signed a Definitive Agreement with Australian company Pitchblende Energy, which is being acquired by ASX-listed Valor Resources, on the North Falcon Uranium Project whereby Pitchblende can earn-in 80% of the project through $3,500,000 in total exploration expenditures, $475,000 in total cash payments over three years and an initial share issuance.

Skyharbour’s goal is to maximize shareholder value through new mineral discoveries, committed long-term partnerships, and the advancement of exploration projects in geopolitically favourable jurisdictions

Skyharbour’s Uranium Project Map in the Athabasca Basin:

http://skyharbourltd.com/_resources/maps/SYH-Athabasca-Map.pdf

To find out more about Skyharbour Resources Ltd. (TSX-V: SYH) visit the Company’s website at www.skyharbourltd.com.

SKYHARBOUR RESOURCES LTD.

“Jordan Trimble”
_________________________________                                        
Jordan Trimble
President and CEO

For further information contact myself or:
Spencer Coulter
Corporate Development and Communications
Skyharbour Resources Ltd.
Telephone: 604-687-3376
Toll Free: 800-567-8181
Facsimile: 604-687-3119
Email: [email protected]

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.

NEW YORK, NY, Jan. 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnologies initiatives, today announced that its Board of Directors (“BOD”) has unanimously voted to terminate its Equity Line of Credit (“ELOC” or “investment Agreement”) due to substantially improved fundamentals, macro-business outlook, and corporate balance sheet. On November 18, 2020 the Company had filed a Form 8-K, disclosing its decision to amend its Investment Agreement to reduce the maximum number of registered shares that are salable thereunder from 76,000,000 shares to 43,000,000 shares (corresponding maximum ELOC dollar amount was reduced from $5,000,000 to $3,000,000 – at that time).

However, due to the recent improvements noted above, the Company’s BOD has further determined to terminate the Investment Agreement Entirely – pursuant to which the ELOC was established. Accordingly, the Company will withdraw its S-1 Registration Statement related to this ELOC.

Link to Form 8-K (Filed on 11/18/2020):  https://www.sec.gov/Archives/edgar/data/1142790/000149315220022012/form8k.htm)

Once this termination is complete, the 43,000,000 shares of TAUG common stock (reserved for the ELOC), will be returned to Treasury and available for future issuance or reserve, if and as needed.

The Company believes that this corporate action sends a message to the investing public, that management is becoming increasingly confident about the Company’s future.  Management has eliminated, through this corporate action, the potential open market pressure that an ELOC may create.

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   

On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)

On October 7, 2020 the Company disclosed a Strategic Alliance with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace, Son of Christopher “The Notorious B.I.G.” Wallace.

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward-looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: [email protected]
Cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com

Attachment

• TAUG

HAMILTON, Ontario, Jan. 07, 2021 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTCQB:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing digital health company that develops innovative Virtual Care software as a service (SaaS) solutions for the Community Healthcare market has retained Lytham Partners, LLC (“Lytham Partners”) to lead a U.S. investor relations program.

For more than 20 years, Lytham Partners has been one of the industry’s leading investor relations firms in the U.S., having created one of the largest and most diverse networks of institutional investors, while creating a framework of best practices in all aspects of corporate and shareholder communications.

“We made significant progress in 2020 in the United States by increasing our penetration beyond our historical markets of Florida and South Texas,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “We are now working with clients across the U.S. and have a clear path to cashflow positive in Q1 2021. Given our recent progress and anticipated growth in 2021, we believe that this is an opportune time to increase awareness of our company within the U.S. investment community. We look forward to working with the team at Lytham Partners, which has a strong understanding of the healthcare technology space and a proven track record of helping public companies communicate their story to the largest and most relevant cross section of institutional investors.”

Ben Shamsian, Vice President of Lytham Partners, said, “Given Reliq’s fast growing and diversified customer base across the United States, we believe the U.S. investment community will be interested to learn more about their unique value proposition and opportunities ahead to create value for shareholders. We look forward to introducing the Company to our platform of investors while keeping shareholders apprised of the developments taking place at the Company.”

In connection with the engagement, Lytham Partners will be compensated USD $6,000 per month.

The Company also announces the granting of stock options under its Stock Option Plan to purchase an aggregate of 500,000 common shares of the Company at an exercise price of $0.415 per share for a five year term. The stock options were granted to the CFO of the Company pursuant to Reliq’s Stock Option Plan and the policies of the TSX Venture Exchange and vest over one year.

About Lytham Partners

For more than 20 years, Lytham Partners has been one of the country’s leading investor relations firms, having created one of the industry’s largest and most diverse networks of institutional investors, while creating a framework of best practices in all aspects of corporate and shareholder communications. In addition to their relationships with many of the industry’s most respected institutional investors, Lytham Partners has spent the past two decades creating an integrated platform that allows its clients far reaching exposure to investors in a consistent and in-depth format. This platform is matched with a communications and positioning approach that is streamlined throughout press releases, conference calls, investor presentations, corporate profiles, and websites. For more information visit our website at www.lythampartners.com.

About Reliq Health

Reliq Health Technologies is a rapidly growing digital health company that specializes in developing innovative Virtual Care software as a service (SaaS) solutions for the Community Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTCQB as RQHTF and on the WKN as A2AJTB.

ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director

For further information please contact:

Company Contact

Investor Relations at [email protected]

Lytham Partners, LLC

Ben Shamsian
New York | Phoenix
Telephone: 646-829-9701
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the “Company“) does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.

BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today announced that it will host a special live, virtual product launch event, Cerence In Motion, to introduce its next-generation conversational AI platform, new cloud products, and broad connected mobility strategy. The event will take place on Tuesday, January 19, 2021 from 10:00 AM to 11:30 AM ET.

Sunny Madra, Vice President, Ford X at Ford Motor Company will join Cerence in Motion as a special guest for a fireside chat. The launch event will be hosted by Cerence CEO Sanjay Dhawan and will include presentations from Prateek Kathpal, CTO; Stefan Ortmanns, EVP & GM, Core Products; Charles Kuai, SVP & GM, Mobility Solutions; and Udo Haiber, SVP of R&D.

The program will focus on new products and strategies that advance connected mobility, including:

• New innovations, built on the latest AI-powered embedded and cloud offerings, for the fastest, most intelligent automotive assistant platform on the market;
• New products that extend drivers’ digital lives to mobility, making consumers’ daily journeys more enjoyable and productive than ever; and,
• New applications for Cerence conversational AI in new mobility industries.

“In our first year as Cerence, we significantly accelerated our pace of innovation, introducing a steady cadence of new products that deliver a safer, more enjoyable journey for everyone,” said Richard Mack, Chief Marketing & Communications Officer, Cerence. “Cerence In Motion on January 19 marks the beginning of the next phase in our journey. We’re excited and proud to share our strategic path and launch a number of new products for AI-powered, voice-first experiences across the mobility ecosystem.”

To learn more and register for Cerence In Motion, visit www.cerence.com/cerence-motion. To learn more about Cerence, visit www.cerence.com, and follow the company on LinkedIn and Twitter.

About Cerence Inc.

Cerence (NASDAQ: CRNC) is the global industry leader in creating unique, moving experiences for the automotive world. As an innovation partner to the world’s leading automakers, it is helping transform how a car feels, responds and learns. Its track record is built on more than 20 years of knowledge and more than 350 million cars on the road today. Whether it’s connected cars, autonomous driving or e-vehicles, Cerence is mapping the road ahead. For more information, visit www.cerence.com.

Contact Information

Kate Hickman
Cerence Inc.
Tel: 339-215-4583
Email: [email protected]

WAYNE, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) — Konica Minolta Healthcare Americas Inc. and strategic partner AGIMED, a leading healthcare distributor in Argentina, jointly announce the implementation of Konica Minolta imaging management solutions across the primary public health hospital system in Córdoba, Argentina’s second largest region. This installation of 34 Picture Archiving and Communication Systems (PACS) with 56 digital systems will allow the health system to convert from film to the more modern digital technology for image acquisition. The tender is part of the PACS digitization and services framework under the Comprehensive Investment Plan for the Modernization of Provincial Hospitals, a government-funded project to further advance the quality of healthcare for Argentinians.

“This order is the culmination of two years working with the provincial health system in the Province of Córdoba to bring the latest information technology to providers throughout the region,” says Germán Dubs, Business Manager at AGIMED. “The project is an important step in accelerating diagnoses, improving clinical workflow and enhancing communication and collaboration among radiologists and other physicians to improve the quality of patient care for the residents of Córdoba. We are proud to partner with Konica Minolta to bring their imaging and informatics solutions to the region.”

The large order is for the main public hospital network in the Province of Córdoba, consisting of 34 hospitals serving more than 3.5 million residents. Once complete, it will represent the largest installed base of Konica Minolta solutions through AGIMED in this region of Argentina. AGIMED is one of the main providers of medical equipment and solutions in the public and private healthcare market in the country.  

“Our imaging and informatics solutions are designed to address the needs of the Latin American market as hospitals, clinics and imaging providers transition from film to a digital imaging environment,” says Ernesto Márquez, General Manager of the Latin American Region for Konica Minolta Healthcare. “AGIMED is one of our initial, valued partners in Argentina and will help lead the introduction of our solutions in Argentina, the third largest market in Latin America and an important segment in our regional strategy.”

Argentina, like much of Latin America, remains a large consumer of medical film. The project represents significant progress toward digitizing medical imaging to enable the adoption of electronic patient records.

“There is a tremendous need for a cost-effective yet robust PACS in the Latin American market and we are committed to delivering the right solution at the right time,” says Antonio Uzcátegui, Director of Healthcare Technology for Latin America at Konica Minolta Healthcare Americas, Inc. “We look forward to continuing our collaboration with AGIMED to help improve radiology workflow that will help increase access to high-quality healthcare for Argentinians.”

About Konica Minolta Healthcare Americas, Inc.

Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. With over 75 years of endless innovation, Konica Minolta is globally recognized as a leader providing cutting-edge technologies and comprehensive support aimed at providing real solutions to meet customer’s needs and helping make better decisions sooner. Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a unit of Konica Minolta, Inc. (TSE:4902). For more information on Konica Minolta Healthcare Americas, Inc., please visit www.konicaminolta.com/medicalusa.

Contact:

Mary Beth Massat
Massat Media
[email protected]
www.konicaminolta.com/medicalusa

MALVERN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the expansion of its commercial organization.

Sales Organization Update

As part of the Company’s previously announced sales organization optimization initiative, the Company recently expanded the size of its sales organization, including the addition of:

• Thirteen new Business Development Managers (“BDMs”), bringing the total number of BDMs to 22
• Nine new NeuroStar Practice Consultants (“NPCs”), bringing the total number of NPCs to 27

In addition, the Company added personnel to its sales management, reimbursement, clinical training and marketing functions.

“We are delighted with the exceptional talent we were able to attract to Neuronetics. Many of these individuals have extensive experience with the capital sale with a trailing treatment session model. And, these individuals share the core values needed to drive the execution of our strategy and company mission,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “We are very excited about what the future holds at Neuronetics and look forward to leveraging the momentum we have built to continue to expand awareness and access to NeuroStar Advanced Therapy for people who are suffering from depression.”

Inducement Grant

In conjunction with this expansion, on January 4, 2021, the Compensation Committee of Neuronetics’ Board of Directors granted restricted stock unit (“RSU”) awards representing an aggregate of 267,358 shares of its common stock to 23 new employees under the Neuronetics, Inc. 2020 Inducement Equity Incentive Plan, (the “2020 Inducement Plan”) in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the continuing employment of the respective RSU recipients.

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Neuronetics (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with Neuronetics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar^® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:

Statements in the press release regarding Neuronetics, Inc. (the “Company”) that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “outlook,” “potential,” “believe,” “expect,” “plan,” “anticipate,” “predict,” “may,” “will,” “could,” “would” and “should” as well as the negative of these terms and similar expressions. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of COVID-19 on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; the Company’s ability to execute its business continuity, operational and budget plans in light of the COVID-19 outbreak; the Company’s ability to achieve or sustain profitable operations due to its history of losses; the Company’s reliance on the sale and usage of its NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of the Company’s salesforce; availability of coverage and reimbursement from third-party payors for treatments using the Company’s products; physician and patient demand for treatments using the Company’s products; developments in respect of competing technologies and therapies for the indications that the Company’s products treat; product defects; the Company’s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company’s recent SEC filings which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in the Company’s expectations.

Investor Contact:

Mark R. Klausner
Westwicke Partners
443-213-0501
[email protected] 

Media Contact:

Chelsey Manko
Vault Communications
610-455-2778
[email protected]

FDA grants RPD and ODD for PRAX-222 for treatment of SCN2A-DEE

FDA grants RPD for PRAX-562 for treatment of SCN2A-DEE and SCN8A-DEE

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted both rare pediatric disease and orphan drug designations for PRAX-222 for the treatment of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE). The FDA has also granted rare pediatric disease designation for PRAX-562 for the treatment of SCN2A-DEE and for the treatment of SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).

“As a company deeply rooted in the genetic drivers of severe pediatric epilepsies, these designations are especially meaningful and validating,” said Marcio Souza, president and chief executive officer of Praxis. “We are committed to drug development for both common and rare CNS diseases and look forward to progressing PRAX-562 and PRAX-222 in the clinic and ultimately to children who are in dire need of new treatment options.”

PRAX-562 is a selective small molecule and is the first persistent sodium current blocker in development for the treatment of a wide range of rare CNS disorders. The clinical development plan for PRAX-562 encompasses exploring the broad potential for the mechanism of action in rare diseases through proof-of-concept trials in two rare types of cephalgia, and then expanding into a range of rare pediatric DEEs, including SCN8A-DEE and SCN2A-DEE. PRAX-562 is currently being evaluated in a Phase 1 clinical trial in adult healthy volunteers.

PRAX-222 is an antisense oligonucleotide that is designed to lower the expression levels of the protein encoded by the SCN2A gene in patients with SCN2A gain-of-function epilepsy. The program is ongoing under a three-way collaboration with Ionis Pharmaceuticals, Inc. and RogCon, Inc. PRAX-222 is currently being evaluated in IND-enabling studies.

“The potential broad utility of PRAX-562 in DEEs and other rare CNS disorders and the precision therapy approach of PRAX-222 represent two differentiated and potentially complementary treatment paradigms inspired by human genetics,” said Steven Petrou, Ph.D., co-founder and chief scientific officer of Praxis. “The FDA granting these designations is an acknowledgement of the critical need to develop treatments for children living with these devastating diseases.”

The FDA’s rare pediatric disease designation program is designed for serious and life-threatening diseases primarily affecting children under the age of 18 with fewer than 200,000 people in the United States. Under the FDA’s rare pediatric disease and voucher programs, subject to FDA approval of a product with such designation, a company may be eligible to receive a priority review voucher that can be redeemed to obtain priority review for any subsequent marketing application or sold or transferred to other companies.

The FDA’s orphan drug designation program is designed to encourage and facilitate the development of investigational treatments for rare diseases that affect fewer than 200,000 people in the United States. The designation provides various development and commercial incentives, including tax credits for clinical research costs, waiver or partial payment of application fees and market exclusivity for seven years following FDA approval.

About SCN2A-DEE/SCN8A-DEE

SCN2A-DEE and SCN8A-DEE are rare developmental and epileptic encephalopathies caused by variants in the SCN2A and SCN8A genes, respectively. Both the SCN2A and SCN8A genes are critical in the formation of sodium channel proteins in the brain, which control the flow of sodium ions into neurons. This movement of sodium ions is a major component of generating electrical signals called action potentials, the way in which the cells communicate. Patients suffer from recurrent, typically drug-resistant seizures which start as early as the first day of life. The seizures can be of multiple different types, up to dozens per day, with poor response to current treatment options. Patients with SCN2A-DEE and SCN8A-DEE have significant cognitive disabilities, ranging from moderate to severe; often movement disorders, such as dystonia or ataxia; and problems in other body systems such as gastrointestinal or ocular. Those with SCN8A-DEE also may experience autonomic features such as increases or decreases in heart rate, abnormal breathing and cyanosis.

About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. Praxis has established a broad portfolio, including five disclosed programs across multiple central nervous system disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.

Investor Contact:
Alex Kane 
Praxis Precision Medicines
[email protected] 
617-300-8481

Media Contact:
Ian Stone
Canale Communications
[email protected]
619-849-5388

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2021, the compensation committee of GBT’s board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).

The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of directors in January 2017 and has been amended and restated from time to time.

About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601, the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650-410-3258
[email protected]

Courtney Roberts (investors)
650-351-7881
[email protected]

NEWARK, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) — ShotSpotter, Inc. (Nasdaq: SSTI), a leader in precision policing solutions that enable law enforcement to more effectively respond to, investigate and deter crime, today reported a dramatic rise of 48 percent in gunshot incidents during 2020 compared with 2019¹, according to the Company’s data that tracks gunfire in more than 100 U.S. cities that use its technology. The increase comes during a year that included a global pandemic, calls for social justice and heightened political divisions.

ShotSpotter gunfire statistics for 2020 showed a spike in gunshot incidents as compared to the prior year in the weeks following George Floyd’s death (May 25). That trend continued during the next four weeks of nationwide protests and, while dropping the last week of June, gunfire levels remained at a significantly higher rate throughout the remainder of the year as compared to the prior year. The 2020 ShotSpotter National Gunfire Trends report showing gunfire incidents per square mile per week, 2020 vs. 2019, is found here.

When broken down by region, the data reveals a 58 percent increase in gunfire in the Midwest – the region with the highest increase. In other regions, the South had the smallest increase in gunshot events with a 19 percent increase year over year, while the Northeast and West experienced similar surges of 40 percent and 42 percent respectively as compared to the prior year. In line with the ShotSpotter data of increased 2020 gunfire rates, independent research group Gun Violence Archive reported a record number of homicides by gun violence this year with more than 19,000 U.S. deaths.

New Year’s Eve – typically an active night due to celebratory gunfire – saw an upswing this year with the ShotSpotter Incident Review Center (IRC) logging an unprecedented 12,266 gunshot alerts in just 24 hours. In comparison, over the past three years the New Year’s Eve numbers averaged 6,803 ShotSpotter alerts in the same timeframe. The 2021 rate is nearly double the three-year average of 6,803 gunshots and up 36 percent from 2020 when the rate was 9,034.

“The startling increase in gunshots and gun violence deaths in 2020 is hopefully an extreme outlier,” said Lynda R. Williams, President of NOBLE (National Organization of Black Law Enforcement Executives). “We do know that last year was unprecedented due to a global pandemic, social justice protests, a divisive national election, and an increase in gun sales.  It is our belief that law enforcement agencies and communities can work hand in hand for public health and safety in the new year.”

“Unfortunately turning the page to 2021 will not magically reduce violent crime, but our hope is that the insight that our unique data provides will motivate policy makers and appropriators to invest more resources and tools to help agencies drive violent crime levels down,” said Ralph A. Clark, President and CEO of ShotSpotter. “We look forward to partnering with agencies in this new year to enable them to be more data driven, proactive and efficient in adopting proven precision policing strategies going forward.”

About ShotSpotter

ShotSpotter (Nasdaq: SSTI) is a leader in precision policing solutions that enable law enforcement officials to more effectively respond to, investigate and deter crime. The company’s products are trusted by more than 100 U.S. cities to help make their communities safer. The platform includes its flagship product, ShotSpotter Respond™, the leading gunshot detection, location and forensic system, and ShotSpotter Connect™, patrol management software to dynamically direct patrol resources to areas of greatest risk and more effectively deter crime. ShotSpotter’s CrimeCenter™ investigative case management software helps detectives connect the dots and share information more effectively to improve case clearance rates. ShotSpotter also serves the corporate and college security markets and has been designated a Great Place to Work^® Company.

For more media information for ShotSpotter, contact:

Media Contact:
Liz Einbinder 
ShotSpotter, Inc. 
+1 (510) 794-3147
[email protected]

Investor Relations Contacts:

Matt Glover
Gateway Investor Relations
+1 (949) 574-3860
[email protected]

JoAnn Horne
Market Street Partners
+1 (415) 445-3240
[email protected]

¹ Annual gunshot data is normalized for growth in customer coverage by using gunshot incidents per square mile.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9bdc94c3-b88f-4506-b525-92c37a6841a2

CINCINNATI, Jan. 07, 2021 (GLOBE NEWSWIRE) — LSI Industries Inc. (NASDAQ: LYTS, or the “Company”), a leading U.S. based manufacturer of indoor/outdoor lighting and graphics solutions, today announced that it will release second quarter fiscal 2021 results before the market opens on Thursday, January 21, 2021. A conference call will be held that same day at 11:00 a.m. ET to review the Company’s financial results, discuss recent events and conduct a question-and-answer session.

A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of LSI Industries’ website at www.lsicorp.com. Individuals can also participate by teleconference dial-in. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software.

Details of the conference call are as follows:

Call Dial-In:	877-407-4018
Conference ID:	13714672
Call Replay:	844-512-2921
Replay Passcode:	13714672

A replay of the conference call will be available between January 21, 2021 and February 4, 2021. To listen to a replay of the teleconference via webcast, please visit the Investor Relations section of LSI Industries’ website at www.lsicorp.com.

ABOUT LSI INDUSTRIES

Headquartered in Blue Ash, Ohio (Greater Cincinnati), LSI Industries is a leading producer of high-performance, American-made lighting solutions. The Company’s strength in outdoor lighting applications creates opportunities for it to introduce additional solutions to its valued customers. LSI’s indoor and outdoor products and services, including its digital and print graphics capabilities, are valued by architects, engineers, distributors and contractors for their quality, reliability and innovation. The Company’s products are used extensively in automotive dealerships, petroleum stations, quick service restaurants, grocery stores and pharmacies, retail establishments, sports complexes, parking lots and garages, and commercial and industrial buildings. LSI has approximately 1,100 employees at seven manufacturing plants in the United States, including its corporate headquarters. Additional information about LSI is available at www.lsicorp.com.

FORWARD-LOOKING STATEMENTS

For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit https://investors.lsicorp.com as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. 

INVESTOR CONTACT

Noel Ryan, IRC
720.778.2415
[email protected]

MEDIA CONTACT

Mike Wallner
Senior Manager, Communications
513.372.3417
[email protected]